Source: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2016 Sep; Vol. 5 (5), pp. 364-73. Date of Electronic Publication: 2016 Mar 23.Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.

Authors : Cotreau MM; AVEO Oncology, Cambridge, MA, USA.; Siebers NM

Subjects: Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*pharmacokinetics ; Cytochrome P-450 CYP3A/Cytochrome P-450 CYP3A/Cytochrome P-450 CYP3A/*metabolism ; Cytochrome P-450 CYP3A Inducers/Cytochrome P-450 CYP3A Inducers/Cytochrome P-450 CYP3A Inducers/*administration & dosage

Source: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2015 Mar; Vol. 4 (2), pp. 137-42. Date of Electronic Publication: 2014 Oct 01.Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Impact on abiraterone pharmacokinetics and safety: Open-label drug-drug interaction studies with ketoconazole and rifampicin.

Authors : Bernard A; Janssen Research & Development, Clinical Pharmacology, Raritan, NJ, USA.; Vaccaro N

Subjects: Abiraterone Acetate/Abiraterone Acetate/Abiraterone Acetate/*pharmacokinetics ; Cytochrome P-450 CYP3A/Cytochrome P-450 CYP3A/Cytochrome P-450 CYP3A/*metabolism ; Cytochrome P-450 CYP3A Inducers/Cytochrome P-450 CYP3A Inducers/Cytochrome P-450 CYP3A Inducers/*administration & dosage

Source: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2015 Jan; Vol. 4 (1), pp. 63-73. Date of Electronic Publication: 2014 Jun 27.Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

The effects of CYP3A4 induction and inhibition on the pharmacokinetics of alisporivir in humans.

Authors : Barve A; Novartis Institutes for Biomedical Research, East Hanover, NJ, USA.; Kovacs SJ

Subjects: Azithromycin/Azithromycin/Azithromycin/*administration & dosage ; Cyclosporine/Cyclosporine/Cyclosporine/*pharmacokinetics ; Cytochrome P-450 CYP3A/Cytochrome P-450 CYP3A/Cytochrome P-450 CYP3A/*metabolism

Source: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2015 Jan; Vol. 4 (1), pp. 25-32. Date of Electronic Publication: 2014 May 26.Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein.

Authors : Groenendaal D; Astellas Pharma Global Development Europe, Leiden, The Netherlands.; Strabach G

Subjects: Antifungal Agents/Antifungal Agents/Antifungal Agents/*administration & dosage ; Azepines/Azepines/Azepines/*pharmacokinetics ; Benzamides/Benzamides/Benzamides/*pharmacokinetics

Source: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2014 May; Vol. 3 (3), pp. 194-201. Date of Electronic Publication: 2014 Mar 03.Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Identification of Novel Inhibitors of DLK Palmitoylation and Signaling by High Content Screening.

Authors : Martin DDO; Shriners Hospitals Pediatric Research Center, Lewis Katz School of Medicine at Temple University, 3500 N. Broad Street, Philadelphia, PA, 19140, USA.; Kanuparthi PS

Subjects: Lipoylation* ; Protein Processing, Post-Translational*; High-Throughput Screening Assays/High-Throughput Screening Assays/High-Throughput Screening Assays/*methods

Source: Scientific reports [Sci Rep] 2019 Mar 06; Vol. 9 (1), pp. 3632. Date of Electronic Publication: 2019 Mar 06.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans.

Authors : Kellerman D; MAP Pharmaceuticals, Inc., USA.; Kori S

Subjects: Cytochrome P-450 CYP3A Inhibitors*; Dihydroergotamine/Dihydroergotamine/Dihydroergotamine/*administration & dosage ; Ketoconazole/Ketoconazole/Ketoconazole/*administration & dosage

Source: Cephalalgia : an international journal of headache [Cephalalgia] 2012 Jan; Vol. 32 (2), pp. 150-8. Date of Electronic Publication: 2011 Dec 15.Publisher: Country of Publication: England NLM ID: 8200710 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-2982

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro.

Authors : Greenblatt DJ; Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts Medical Center, Boston, MA, USA. ; Venkatakrishnan K

Subjects: Cytochrome P-450 CYP3A Inhibitors*; Antifungal Agents/Antifungal Agents/Antifungal Agents/*pharmacology ; Ketoconazole/Ketoconazole/Ketoconazole/*pharmacology

Source: Xenobiotica; the fate of foreign compounds in biological systems [Xenobiotica] 2010 Oct; Vol. 40 (10), pp. 713-20.Publisher: Informa Healthcare Country of Publication: England NLM ID: 1306665 Publication Model: Print Cited Medium: Internet ISSN: 1366-5928

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus.

Authors : Boni JP; Department of Clinical Pharmacology, Wyeth Research, 500 Arcola Road, Collegeville, PA 19426, USA. ; Leister C

Subjects: Cytochrome P-450 CYP3A Inhibitors*; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacokinetics ; Enzyme Inhibitors/Enzyme Inhibitors/Enzyme Inhibitors/*pharmacology

Source: British journal of cancer [Br J Cancer] 2008 Jun 03; Vol. 98 (11), pp. 1797-802. Date of Electronic Publication: 2008 May 06.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies.

Authors : Martin P; AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, SK10 4TF, UK. .; Gillen M

Subjects: Drug Interactions*; Cytochrome P-450 CYP3A Inducers/Cytochrome P-450 CYP3A Inducers/Cytochrome P-450 CYP3A Inducers/*therapeutic use ; Cytochrome P-450 CYP3A Inhibitors/Cytochrome P-450 CYP3A Inhibitors/Cytochrome P-450 CYP3A Inhibitors/*therapeutic use

Source: Drugs in R&D [Drugs R D] 2016 Mar; Vol. 16 (1), pp. 81-92.Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 100883647 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

In Silico Predictions and In Vivo Results of Drug-Drug Interactions by Ketoconazole and Verapamil on AZD1305, a Combined Ion Channel Blocker and a Sensitive CYP3A4 Substrate.

Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.

Impact on abiraterone pharmacokinetics and safety: Open-label drug-drug interaction studies with ketoconazole and rifampicin.

The effects of CYP3A4 induction and inhibition on the pharmacokinetics of alisporivir in humans.

The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein.

Identification of Novel Inhibitors of DLK Palmitoylation and Signaling by High Content Screening.

Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans.

Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro.

Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus.

Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies.

اتصل بنا

اتبع